Interferon in the treatment of cutaneous T-cell lymphoma - PubMed (original) (raw)

Review

Interferon in the treatment of cutaneous T-cell lymphoma

Elise A Olsen. Dermatol Ther. 2003.

Abstract

Interferons are polypeptides with a broad range of in vivo effects that have shown efficacy in cutaneous T-cell lymphoma (CTCL). Particularly useful is alfa interferon (IFN) which, as a single agent, has shown partial remission rates of > 50% and complete responses of > 20%. Side-effects are predictable, generally well tolerated and dose-related. The efficacy of IFN has increased with combination therapy without any significant increase in attendant side-effects. An update on the specifics of the different IFN subtypes, their inherent biologic activity, pharmacokinetics, efficacy and safety in CTCL is presented in this paper.

PubMed Disclaimer

Similar articles

• Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
  Kannangara AP, Levitan D, Fleischer AB Jr. Kannangara AP, et al. J Dermatolog Treat. 2009;20(3):169-76. doi: 10.1080/09546630802562427. J Dermatolog Treat. 2009. PMID: 19016373
• Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
  Aviles A, Neri N, Fernandez-Diez J, Silva L, Nambo MJ. Aviles A, et al. Hematology. 2015 Oct;20(9):538-42. doi: 10.1179/1607845415Y.0000000002. Epub 2015 Jan 16. Hematology. 2015. PMID: 25592781 Clinical Trial.
• Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
  Wollina U, Looks A, Meyer J, Knopf B, Koch HJ, Liebold K, Hipler UC. Wollina U, et al. J Am Acad Dermatol. 2001 Feb;44(2):253-60. doi: 10.1067/mjd.2001.110645. J Am Acad Dermatol. 2001. PMID: 11174383 Clinical Trial.
• [Interferon-alpha in cutaneous T-cell lymphoma].
  Knobler R. Knobler R. Wien Med Wochenschr. 1993;143(16-17):435-7. Wien Med Wochenschr. 1993. PMID: 8273368 Review. German.
• Phototherapy for cutaneous T-cell lymphoma.
  Baron ED, Stevens SR. Baron ED, et al. Dermatol Ther. 2003;16(4):303-10. doi: 10.1111/j.1396-0296.2003.01642.x. Dermatol Ther. 2003. PMID: 14686973 Review.

Cited by

• Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas.
  Dummer R, Eichmüller S, Gellrich S, Assaf C, Dreno B, Schiller M, Dereure O, Baudard M, Bagot M, Khammari A, Bleuzen P, Bataille V, Derbij A, Wiedemann N, Waterboer T, Lusky M, Acres B, Urosevic-Maiwald M. Dummer R, et al. Mol Ther. 2010 Jun;18(6):1244-7. doi: 10.1038/mt.2010.52. Epub 2010 Apr 6. Mol Ther. 2010. PMID: 20372104 Free PMC article. Clinical Trial.
• Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and Sezary syndrome. Prospective trial (NCT02323659).
  Chmielowska E, Sokołowska-Wojdyło M, Olszewska B, Studziński M, Grzanka-Gadzińska A, Zabłotna M, Olek-Hrab K, Iwanowski T, Olejniczak M, Krause A, Giebel S. Chmielowska E, et al. Postepy Dermatol Alergol. 2021 Apr;38(2):295-301. doi: 10.5114/ada.2021.106206. Epub 2021 May 22. Postepy Dermatol Alergol. 2021. PMID: 36751548 Free PMC article.
• Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel.
  Denis D, Beneton N, Laribi K, Maillard H. Denis D, et al. Cancer Manag Res. 2019 Mar 20;11:2241-2251. doi: 10.2147/CMAR.S138661. eCollection 2019. Cancer Manag Res. 2019. PMID: 30962713 Free PMC article. Review.
• Mycosis fungoides: therapeutic difficulties.
  Adamska K, Olek-Hrab K, Misterska M, Teresiak-Mikołajczak E, Silny W, Żaba RW, Adamski Z, Pawlaczyk M. Adamska K, et al. Postepy Dermatol Alergol. 2015 Oct;32(5):404-8. doi: 10.5114/pdia.2014.44005. Epub 2015 Oct 29. Postepy Dermatol Alergol. 2015. PMID: 26759552 Free PMC article. No abstract available.
• Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies.
  Stergiou IE, Tsironis C, Papadakos SP, Tsitsilonis OE, Dimopoulos MA, Theocharis S. Stergiou IE, et al. Int J Mol Sci. 2024 Feb 17;25(4):2369. doi: 10.3390/ijms25042369. Int J Mol Sci. 2024. PMID: 38397043 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information